A Signature Based on Five Immune-related Genes to Predict the Survival and Immune Characteristics of Neuroblastoma

Overview

Journal BMC Med Genomics

Publisher Biomed Central

Specialty Genetics

Date 2022 Nov 24

PMID 36419120

Authors

Kexin Ma

Peipei Zhang

Yu Xia

Lin Dong

Ying Li

Liu Liu

Yajuan Liu

Youjun Wang

Affiliations

Soon will be listed here.

Abstract

Background: MYCN amplification (MNA) has been proved to be related to poor prognosis in neuroblastoma (NBL), but the MYCN-related immune signatures and genes remain unclear.

Methods: Enrichment analysis was used to identify the significant enrichment pathways of differentially expressed immune-related genes (DEIRGs). Weight gene coexpression network analysis (WGCNA) was applied to reveal the correlation between these DEIRGs and MYCN status. Univariate and multivariate Cox analyses were used to construct risk model. The relevant fractions of immune cells were evaluated by CIBERSORT and single-sample gene set enrichment analysis (ssGSEA).

Results: Five genes, including CHGA, PTGER1, SHC3, PLXNC1, and TRIM55 were enrolled into the risk model. Kaplan-Meier survival analysis and receiver operating characteristic (ROC) curve showed that our model performed well in predicting the outcomes of NBL (3-years AUC = 0.720, 5-year AUC = 0.775, 10-years AUC = 0.782), which has been validated in the GSE49711 dataset and the E-MTAB-8248 dataset. By comparing with the tumor immune dysfunction and exclusion (TIDE) and tumor inflammation signature (TIS), we further proved that our model is reliable. Univariate and multivariate Cox regression analyses indicated that the risk score, age, and MYCN can serve as independent prognostic factors in the E-MATB-8248. Functional enrichment analysis showed the DEIRGs were enriched in leukocyte adhesion-related signaling pathways. Gene set enrichment analysis (GSEA) revealed the significantly enriched pathways of the five MYCN-related DEIRGs. The risk score was negatively correlated with the immune checkpoint CD274 (PD-L1) but no significant difference with the TMB. We also confirmed the prognostic value of our model in predicting immunotherapeutics.

Conclusion: We constructed and verified a signature based on DEIRG that related to MNA and predicted the survival of NBL based on relevant immune signatures. These findings could provide help for predicting prognosis and developing immunotherapy in NBL.

Citing Articles

Predictive role of SLC1A5 in neuroblastoma prognosis and immunotherapy.

Cheng J, Sun M, Dong X, Yang Y, Qin X, Zhou X BMC Cancer. 2025; 25(1):161.

PMID: 39875895 PMC: 11773968. DOI: 10.1186/s12885-025-13560-y.

Synergistic machine learning models utilizing ferroptosis-related genes for improved neuroblastoma outcome prediction.

Cheng J, Dong X, Yang Y, Qin X, Zhou X, Zhang D Transl Pediatr. 2025; 13(12):2164-2182.

PMID: 39822999 PMC: 11732634. DOI: 10.21037/tp-24-323.

Bioinformatics-Based Identification of Key Prognostic Genes in Neuroblastoma with a Focus on Immune Cell Infiltration and Diagnostic Potential of VGF.

Guo Q, Xiao Y, Chu J, Sun Y, Li S, Zhang S Pharmgenomics Pers Med. 2024; 17:453-472.

PMID: 39403102 PMC: 11472764. DOI: 10.2147/PGPM.S461072.

Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.

Nokchan N, Suthapot P, Choochuen P, Khongcharoen N, Hongeng S, Anurathapan U J Pers Med. 2024; 14(9).

PMID: 39338204 PMC: 11433071. DOI: 10.3390/jpm14090950.

Comprehensive analysis identifies ubiquitin ligase FBXO42 as a tumor-promoting factor in neuroblastoma.

Zhou J, Li Q, Deng X, Peng L, Sun J, Zhang Y Sci Rep. 2024; 14(1):18697.

PMID: 39134694 PMC: 11319589. DOI: 10.1038/s41598-024-69760-2.

References

Itcho K, Oki K, Kobuke K, Yoshii Y, Ohno H, Yoneda M . Aberrant G protein-receptor expression is associated with DNA methylation in aldosterone-producing adenoma. Mol Cell Endocrinol. 2017; 461:100-104. DOI: 10.1016/j.mce.2017.08.019. View

Thompson D, Vo K, London W, Fischer M, Ambros P, Nakagawara A . Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer. 2015; 122(6):935-45. PMC: 4777644. DOI: 10.1002/cncr.29848. View

Huang M, Weiss W . Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013; 3(10):a014415. PMC: 3784814. DOI: 10.1101/cshperspect.a014415. View

Liao Z, Yao H, Wei J, Feng Z, Chen W, Luo J . Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma. Transl Androl Urol. 2021; 10(4):1607-1619. PMC: 8100830. DOI: 10.21037/tau-20-1348. View

Kang W, Hu J, Zhao Q, Song F . Identification of an Autophagy-Related Risk Signature Correlates With Immunophenotype and Predicts Immune Checkpoint Blockade Efficacy of Neuroblastoma. Front Cell Dev Biol. 2021; 9:731380. PMC: 8567030. DOI: 10.3389/fcell.2021.731380. View

Westermann F, Muth D, Benner A, Bauer T, Henrich K, Oberthuer A . Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol. 2008; 9(10):R150. PMC: 2760877. DOI: 10.1186/gb-2008-9-10-r150. View

Southgate H, Chen L, Curtin N, Tweddle D . Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma. Front Oncol. 2020; 10:371. PMC: 7145987. DOI: 10.3389/fonc.2020.00371. View

Zhang C, Liu J, Wang J, Hu W, Feng Z . The emerging role of leukemia inhibitory factor in cancer and therapy. Pharmacol Ther. 2020; 221:107754. PMC: 8084904. DOI: 10.1016/j.pharmthera.2020.107754. View

Dominguez-Sola D, Gautier J . MYC and the control of DNA replication. Cold Spring Harb Perspect Med. 2014; 4(6). PMC: 4031955. DOI: 10.1101/cshperspect.a014423. View

10.

Kanehisa M, Goto S . KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999; 28(1):27-30. PMC: 102409. DOI: 10.1093/nar/28.1.27. View

11.

Zhang X, Shao S, Li L . Characterization of Class-3 Semaphorin Receptors, Neuropilins and Plexins, as Therapeutic Targets in a Pan-Cancer Study. Cancers (Basel). 2020; 12(7). PMC: 7409005. DOI: 10.3390/cancers12071816. View

12.

Maris J . Recent advances in neuroblastoma. N Engl J Med. 2010; 362(23):2202-11. PMC: 3306838. DOI: 10.1056/NEJMra0804577. View

13.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

14.

Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

15.

Perel Y, Amrein L, Dobremez E, Rivel J, Daniel J, Landry M . Galanin and galanin receptor expression in neuroblastic tumours: correlation with their differentiation status. Br J Cancer. 2002; 86(1):117-22. PMC: 2746536. DOI: 10.1038/sj.bjc.6600019. View

16.

Guo T, Zhang Z, Zhu L, Chen W, Ding Y, Li W . TRIM55 suppresses malignant biological behavior of lung adenocarcinoma cells by increasing protein degradation of Snail1. Cancer Biol Ther. 2022; 23(1):17-26. PMC: 8812808. DOI: 10.1080/15384047.2021.2004835. View

17.

Kim E, Park K, Chung S, Sheen Y, Moon D, Song Y . Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway. J Pharmacol Exp Ther. 2003; 307(2):505-17. DOI: 10.1124/jpet.103.053876. View

18.

Wang H, Yin J, Hong Y, Ren A, Wang H, Li M . SCG2 is a Prognostic Biomarker Associated With Immune Infiltration and Macrophage Polarization in Colorectal Cancer. Front Cell Dev Biol. 2022; 9:795133. PMC: 8763391. DOI: 10.3389/fcell.2021.795133. View

19.

Shi Y, Yuan J, Rraklli V, Maxymovitz E, Cipullo M, Liu M . Aberrant splicing in neuroblastoma generates RNA-fusion transcripts and provides vulnerability to spliceosome inhibitors. Nucleic Acids Res. 2021; 49(5):2509-2521. PMC: 7969022. DOI: 10.1093/nar/gkab054. View

20.

Mlakar V, Jurkovic Mlakar S, Lopez G, Maris J, Ansari M, Gumy-Pause F . 11q deletion in neuroblastoma: a review of biological and clinical implications. Mol Cancer. 2017; 16(1):114. PMC: 5492892. DOI: 10.1186/s12943-017-0686-8. View